カワムラ ヒデマサ   KAWAMURA Hidemasa
  河村 英将
   所属   埼玉医科大学  医学部 総合医療センター 放射線科(画像診断・核医学科、放射線腫瘍科)
   職種   教授
論文種別 学術雑誌(原著)
言語種別 英語
査読の有無 査読なし
表題 A Japanese registry study and systematic review of particle therapy for renal cell carcinoma.
掲載誌名 正式名:Journal of radiation research
掲載区分国外
著者・共著者 Hitoshi Ishikawa,Takeshi Arimura,Kazushi Maruo,Hidemasa Kawamura,Shingo Toyama,Takashi Ogino,Tomoaki Okimoto,Masao Murakami,Yoshitaka Sato,Kentaro Nishioka,Masayuki Araya,Hisateru Ohba,Kensuke Umehara,Hidefumi Aoyama,Wataru Obara,Haruhito Azuma,Hiroshi Tsuji,Hideyuki Sakurai
発行年月 2023/04/12
概要 The feasibility and efficacy of particle beam therapy (PBT) using protons or carbon ions were compared with those of photon-based stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC) via a systematic review and nationwide registry for PBT (Japanese Society for Radiation Oncology [JASTRO] particle therapy committee). Between July 2016 and May 2019, 20 patients with non-metastatic RCC who were treated at six Japanese institutes (using protons at three, using carbon ions at the other three) were registered in the nationwide database and followed up prospectively. The 20 patients comprised 15 men and had a median age of 67 (range: 57-88) years. The total radiation dose was 66-79.6 Gy (relative biological effectiveness [RBE]). Over a median follow up of 31 months, the 3-year rates of overall survival (OS) and local control (LC) were 100% and 94.4%, respectively. No grade ≥ 3 toxicities were observed. Based on a random effects model, a meta-analysis including the present results revealed 3-year OS rates after SBRT and PBT of 75.3% (95% CI: 57.3-86.6) and 94.3% (95% CI: 86.8-97.6), respectively (P = 0.005), but the difference in LC rates between the two methods was not observed (P = 0.63). PBT is expected to have similar if not better treatment results compared with SBRT for primary renal cancer. In particular, PBT was shown to be effective even for large RCC and could provide a therapeutic option when SBRT is not indicated.
DOI 10.1093/jrr/rrad010
PMID 37045797